VJHemOnc Podcast

The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts - from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com

VJHemOnc Podcast is a health podcast hosted by VJHemOnc, with 200 episodes on record and a Required Pod Score of 80.

VJHemOnc hosts VJHemOnc Podcast, a health show with 200 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #355

  Personalizing BTK Inhibitor Therapy in CLL: from treatment selection to long-term management

  Oct 2, 202622 min

  This VJHemOnc podcast explores how BTK inhibitor therapy can be personalized for patients with chronic lymphocytic leukemia (CLL), considering disease biology, patient characteristics and treatment goals. Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses frontline treatment selection, molecular risk and factors influencing BTK inhibitor choice, while Florian Simon, MD, University Hospital Cologne, Cologne, Germany, examines cardiovascular toxicity and treatment considerations in older patients and those with comorbidities. Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses quality of life and shared decision-making, and Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, explores BTK inhibitor selectivity, safety and treatment options following covalent BTK inhibitor failure.

  ListenShow Notes
• 

  Episode #354

  Using BTK inhibitors in lymphoma: practical considerations for community physicians

  Sep 11, 202623 min

  This episode of the VJHemOnc podcast, featuring Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, focuses on the practical use of BTK inhibitors (BTKis) in non-Hodgkin lymphoma (NHL). Dr Kamdar begins by discussing which factors guide patient selection for BTKi therapy and outlines how to choose among available agents. She then shares valuable insights on toxicity management, approaching patients with cardiovascular comorbidities, and monitoring treatment response and progression. Finally, Dr Kamdar leaves community physicians with three practical takeaways for successfully using BTKis in everyday clinical practice.

  ListenShow Notes
• 

  Episode #353

  AAV gene therapy in hemophilia: progress, challenges and what comes next

  Sep 3, 202624 min

  This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of AAV-based approaches and the development of next-generation strategies. Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, discusses the limitations of AAV gene therapy in hemophilia A, including factor VIII engineering, durability, and liver toxicity. He also examines potential malignancy risks associated with AAV integration and the importance of long-term surveillance following treatment. Finally, Dr Kaczmarek discusses emerging non-AAV approaches, including lentiviral gene therapy, targeted gene insertion, and gene editing, and their potential to address some of the limitations of current gene therapy approaches.

  ListenShow Notes
• 

  Episode #352

  Clinical considerations in MCL management: frailty assessment, the multidisciplinary team & managing the use of BTKis

  Aug 26, 202618 min

  This VJHemOnc podcast explores the evolving management of mantle cell lymphoma (MCL), from assessing patient fitness to sequencing therapy after BTK inhibitor progression. Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, and Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, discuss assessing fitness and frailty, while Craig Portell, MD, University of Virginia, Charlottesville, VA, outlines the multidisciplinary approach to MCL care. Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, reviews frontline sequencing, including using MRD status to guide transplant decisions, and Dr Phillips and Dr Portell discuss managing patients with higher-risk disease features. Dr Portell also addresses toxicity and treatment burden with long-term BTK inhibitor use. To conclude, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Dr Karimi highlight emerging options after BTK inhibitor progression, including non-covalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, and bispecific antibodies.

  ListenShow Notes
• 

  Episode #351

  Sequencing therapies in multiple myeloma: navigating an expanding treatment landscape

  Aug 24, 202624 min

  This VJHemOnc podcast explores the evolving treatment landscape in multiple myeloma, focusing on treatment selection and sequencing across the disease course. Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses shared decision-making in frontline treatment, while Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, explores sequencing CAR T-cell therapies and bispecific antibodies, including the choice between BCMA- and GPRC5D-directed approaches. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, reviews updated findings from the MajesTEC-3 trial (NCT05083169) of teclistamab plus daratumumab in high-risk disease, and Peter Voorhees discusses Phase III MonumenTAL-3 (NCT05455320) data evaluating talquetamab plus daratumumab, with or without pomalidomide. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, highlights strategies for managing infections associated with bispecific antibodies, while Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the transition towards community-based delivery of bispecific therapies.

  ListenShow Notes

Recent guests on VJHemOnc Podcast. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.